Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Table 3 Antitumor activity

Response evaluation (N = 22)	n	% (95% CI) or median (range)
ORR^a,b, % (95% CI)	2	9 (1–29)
CR	0	0 (0–15)
PR	2	9 (1–29)
SD	13	59 (36–79)
PD	7	32 (14–55)
CBR^b, % (95% CI)	11	50 (28–72)
SD ≥6 months, % (95% CI)	9	69 (39–91)
TTR (months), median (range)	2	5 (4–5)
DOR (months), median (range)	2	14 (8–20)
Follow-up duration (months), median (range)	22	31 (7–34)

Abbreviations: CBR clinical benefit rate, CR complete response, DOR duration of response; NR not reached, ORR objective response rate, PD progressive disease, PR partial response, SD stable disease, TTR time to response
^aORR = CR + PR
^bConfirmed by investigator review
^cCBR = CR + PR + SD ≥6 months

ISSN: 1471-2407